
Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.

May 3, 2022
In 2005, Pfizer launched a Phase 1 trial for the kinase inhibitor crizotinib. Six years later, it was approved, thanks..
Read article

February 9, 2017
Inside an Oncology Statistician's Toolkit
In this blog, Adam Hamm, PhD, Director Biostatistics at Cytel shares some of the most important knowledge he uses..
Read article

August 31, 2016
An Introduction to BLRM
Traditional rule-based approaches to dose escalation such as 3+3 are widely used in early clinical development. They..
Read article

August 23, 2016
How does the T-Statistic stack up for finding MTD?
At the recent JSM meeting in Chicago, Cytel's Jim Bolognese presented the results of work he has conducted evaluating..
Read article

July 21, 2016
Webinar Replay: Single and Double Agent Dose Escalation Designs
Did you miss our webinar on Single and Dual Agent Dose escalation designs earlier in the year? In this blog..
Read article
November 10, 2015
Bayesian Dose Escalation Designs for Late Onset Toxicity
Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods..
Read article
November 18, 2014
A Bayesian Industry Approach to Phase I Combination Trials in Oncology
Statisticians and scientists at Novartis have been at the forefront of developing a new method in early phase oncology..
Read article
September 4, 2014
Adaptive Designs for Evidence Based Oncology: Insights from the Experts
Imagine if we were to count the number of possible reasons that investigators might have for monitoring a biomarker..
Read article